Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05038098 · ClinicalTrials.gov registry record · Phase 1
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05038098: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT05038098 is a Phase 1 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05038098, a Phase 1 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase I finds out the possible benefits and/or side effects of using magnetic tracer FerroTrace and the fluorescent dye indocyanine green to identify the lymph nodes that cancer is most likely to have spread to in patients with gastric cancer that are undergoing gastrectomy. Using FerroTrace in combination with the indocyanine green dye may help researchers better detect the disease.
Primary Outcome
The Bayesian method by Thall et al. will be applied for interim toxicity monitoring. Toxicities are defined as any grade III or greater toxicities attributable to FerroTrace injection, which occur within 24 hours of the injection. Will summarize the rate of adverse events (AEs) in all patients and by cohort, along with the exact 95% confidence interval.
Interventions
- DRUG Indocyanine Green
- PROCEDURE Gastrectomy
- OTHER Iron Conjugated Polymers in Saline Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2027-02-02 |
| Phase | Phase 1 |
What is known before NCT05038098 opens enrollment
NCT05038098 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 3 interventions - of which Indocyanine Green is the first listed.
NCT05038098 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05038098 about?
NCT05038098 is a clinical study titled "Magnetic Sentinel Lymph Node Mapping in Gastric Cancer". This phase I finds out the possible benefits and/or side effects of using magnetic tracer FerroTrace and the fluorescent dye indocyanine green to identify the lymph nodes that cancer is most likely to have spread to in patients with gastric cancer that are undergoing gastrectomy. Using FerroTrace in...
What is the current status of trial NCT05038098?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-03-31. Estimated completion is 2027-02-02.
What interventions are being tested in trial NCT05038098?
The interventions under investigation include: Indocyanine Green (DRUG), Gastrectomy (PROCEDURE), Iron Conjugated Polymers in Saline Suspension (OTHER).
Who is sponsoring clinical trial NCT05038098?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05038098's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI